Tetracaine Combined Spinal Epidural (CSE) Versus Bupivacaine CSE
Study Details
Study Description
Brief Summary
The investigators hypothesis is that spinal tetracaine with fentanyl and epinephrine used for CSE labor analgesia volume will last a significantly longer period of time that that of spinal bupivacaine with fentanyl. After informed consent is obtained for the study, subjects meeting criteria when analgesia is requested will be randomized to receive a combined spinal-epidural containing either tetracaine 2 mg with fentanyl and epinephrine or bupivacaine 2 mg with fentanyl and epinephrine.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 4 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: tetracaine 2mg
|
Drug: Tetracaine
Tetracaine 2mg will be combined with Fentanyl 20 mcg and Epinephrine 50 mcg to treat labor pain.
|
Active Comparator: Bupivacaine 2 mg
|
Drug: Bupivacaine
Bupivacaine 2 mg combined with fentanyl 20 mcg and Epinephrine 50 mcg will be used to treat labor pain.
|
Outcome Measures
Primary Outcome Measures
- Spinal Analgesic Duration [1-2 hrs]
duration of time in minutes from the time the combined spinal epidural is placed until the participant requests additional analgesia; at that time the epidural was dosed and study participation was complete
Eligibility Criteria
Criteria
Inclusion Criteria:
-
early labor (>=2cm but =<6cm cervical dilation)
-
at least 12 years of age
-
have an assigned ASA physical status 1 or 2
-
singleton pregnancy
Exclusion Criteria:
-
contraindications to neuraxial anesthesia
-
with allergies to drugs used in the study
-
have an assigned ASA status 3 or 4
-
advanced labor (> 6cm cervical dilation)
-
less than 12 years of age
-
Patients with the potential for distorted epidural anatomy, such as Harrington rods or prior back surgery, will also be excluded.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Forsyth Medical Center- OB Anesthesia dept | Winston-Salem | North Carolina | United States | 27103 |
Sponsors and Collaborators
- Wake Forest University
Investigators
- Principal Investigator: Peter H. Pan, MD, WFUHS
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IRB 9824
Study Results
Participant Flow
Recruitment Details | Participants were approached after admission to the labor and delivery unit of our hospital about participation in this study |
---|---|
Pre-assignment Detail |
Arm/Group Title | Tetracaine 2mg | Bupivacaine 2 mg |
---|---|---|
Arm/Group Description | Tetracaine: Tetracaine 2mg will be combined with Fentanyl 20 mcg and Epinephrine 50 mcg to treat labor pain. | Bupivacaine: Bupivacaine 2 mg combined with fentanyl 20 mcg and Epinephrine 50 mcg will be used to treat labor pain. |
Period Title: Overall Study | ||
STARTED | 23 | 23 |
COMPLETED | 23 | 23 |
NOT COMPLETED | 0 | 0 |
Baseline Characteristics
Arm/Group Title | Tetracaine 2mg | Bupivacaine 2 mg | Total |
---|---|---|---|
Arm/Group Description | Tetracaine: Tetracaine 2mg will be combined with Fentanyl 20 mcg and Epinephrine 50 mcg to treat labor pain. | Bupivacaine: Bupivacaine 2 mg combined with fentanyl 20 mcg and Epinephrine 50 mcg will be used to treat labor pain. | Total of all reporting groups |
Overall Participants | 23 | 23 | 46 |
Age (Count of Participants) | |||
<=18 years |
0
0%
|
0
0%
|
0
0%
|
Between 18 and 65 years |
23
100%
|
23
100%
|
46
100%
|
>=65 years |
0
0%
|
0
0%
|
0
0%
|
Sex: Female, Male (Count of Participants) | |||
Female |
23
100%
|
23
100%
|
46
100%
|
Male |
0
0%
|
0
0%
|
0
0%
|
Race/Ethnicity, Customized (Count of Participants) | |||
white |
18
78.3%
|
17
73.9%
|
35
76.1%
|
african american |
5
21.7%
|
2
8.7%
|
7
15.2%
|
hispanic |
0
0%
|
3
13%
|
3
6.5%
|
other |
0
0%
|
1
4.3%
|
1
2.2%
|
Region of Enrollment (participants) [Number] | |||
United States |
23
100%
|
23
100%
|
46
100%
|
Outcome Measures
Title | Spinal Analgesic Duration |
---|---|
Description | duration of time in minutes from the time the combined spinal epidural is placed until the participant requests additional analgesia; at that time the epidural was dosed and study participation was complete |
Time Frame | 1-2 hrs |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Tetracaine 2mg | Bupivacaine 2 mg |
---|---|---|
Arm/Group Description | Tetracaine: Tetracaine 2mg will be combined with Fentanyl 20 mcg and Epinephrine 50 mcg to treat labor pain. | Bupivacaine: Bupivacaine 2 mg combined with fentanyl 20 mcg and Epinephrine 50 mcg will be used to treat labor pain. |
Measure Participants | 23 | 23 |
Mean (Standard Deviation) [minutes] |
92.68
(46.71)
|
89.61
(27.39)
|
Statistical Analysis 1
Statistical Analysis Overview | Comparison Group Selection | Tetracaine 2mg |
---|---|---|
Comments | ||
Type of Statistical Test | Other | |
Comments | unpaired t-test | |
Statistical Test of Hypothesis | p-Value | >0.05 |
Comments | ||
Method | unpaired t-test compared between groups | |
Comments |
Statistical Analysis 2
Statistical Analysis Overview | Comparison Group Selection | Bupivacaine 2 mg |
---|---|---|
Comments | ||
Type of Statistical Test | Other | |
Comments | unpaired t-test compared between groups | |
Statistical Test of Hypothesis | p-Value | >0.05 |
Comments | ||
Method | unpaired t-test compared between groups | |
Comments |
Adverse Events
Time Frame | ||||
---|---|---|---|---|
Adverse Event Reporting Description | ||||
Arm/Group Title | Tetracaine 2mg | Bupivacaine 2 mg | ||
Arm/Group Description | Tetracaine: Tetracaine 2mg will be combined with Fentanyl 20 mcg and Epinephrine 50 mcg to treat labor pain. | Bupivacaine: Bupivacaine 2 mg combined with fentanyl 20 mcg and Epinephrine 50 mcg will be used to treat labor pain. | ||
All Cause Mortality |
||||
Tetracaine 2mg | Bupivacaine 2 mg | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 0/23 (0%) | 0/23 (0%) | ||
Serious Adverse Events |
||||
Tetracaine 2mg | Bupivacaine 2 mg | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 0/23 (0%) | 0/23 (0%) | ||
Other (Not Including Serious) Adverse Events |
||||
Tetracaine 2mg | Bupivacaine 2 mg | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 0/23 (0%) | 0/23 (0%) |
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
Name/Title | Peter H. Pan MD, MSEE |
---|---|
Organization | Wake Forest School of Medicine-Anesthesiology |
Phone | 336-718-8278 |
ppan@wakehealth.edu |
- IRB 9824